Compare ISD & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISD | DNA |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | 485 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.8M | 455.8M |
| IPO Year | N/A | N/A |
| Metric | ISD | DNA |
|---|---|---|
| Price | $12.86 | $8.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 98.2K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.53 | $5.37 |
| 52 Week High | $14.79 | $17.58 |
| Indicator | ISD | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 35.61 | 47.31 |
| Support Level | $12.75 | $7.59 |
| Resistance Level | $14.67 | $9.58 |
| Average True Range (ATR) | 0.14 | 0.76 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 26.19 | 30.18 |
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The fund's primary investment objective is to provide a high level of current income, with its secondary objective being capital appreciation. It invests at least eighty percent of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.